$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

$avdl Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000101247722000004 Filed on March 16, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Gross Profit	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Gross Profit Margin
Selling, General & Admin	$21.03M	$68.50M	$8.970M
YoY Change	134.4%	111.37%	17.1%
% of Gross Profit
Research & Development	$2.110M	$17.10M	$5.290M
YoY Change	-60.11%	-16.33%	-31.83%
% of Gross Profit
Depreciation & Amortization	$201.0K	$97.00K	$390.0K
YoY Change	-48.46%	-66.2%	-51.25%
% of Gross Profit
Operating Expenses	$23.14M	$85.60M	$14.26M
YoY Change	62.24%	61.98%	-8.77%
Operating Profit	-$23.14M	-$85.55M	-$14.26M
YoY Change	62.24%	-1571.13%	102.27%
Interest Expense	-$4.154M	$9.942M	-$3.310M
YoY Change	25.5%	-23.49%	-29.12%
% of Operating Profit
Other Income/Expense, Net	$646.0K	$0.00	$3.440M
YoY Change	-81.22%	-100.0%	2766.67%
Pretax Income	-$26.64M	-$93.15M	-$14.13M
YoY Change	88.56%	1732.84%	20.36%
Income Tax	-$4.343M	-$15.82M	-$2.850M
% Of Pretax Income
Net Earnings	-$22.30M	-$77.33M	-$11.28M
YoY Change	97.7%	-1200.3%	311.68%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.32
Diluted Earnings Per Share	-$380.4K	-$1.32	-$193.2K
COMMON SHARES
Basic Shares Outstanding	58.62M shares	58.54M shares	58.27M shares
Diluted Shares Outstanding		58.54M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$157.2M	$157.2M	$222.9M
YoY Change	-29.47%	-29.47%	247.2%
Cash & Equivalents	$50.71M	$50.71M	$71.72M
Short-Term Investments	$106.5M	$106.5M	$151.2M
Other Short-Term Assets	$271.0K	$3.450M	$798.0K
YoY Change	-66.04%	130.0%	645.79%
Inventory			$0.00
Prepaid Expenses	$3.179M		$1.018M
Receivables	$279.0K	$279.0K	$0.00
Other Receivables	$31.54M	$31.54M	$22.30M
Total Short-Term Assets	$192.5M	$192.5M	$263.5M
YoY Change	-26.94%	-26.95%	219.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$285.0K	$2.937M	$359.0K
YoY Change	-20.61%	-2.1%	-34.01%
Goodwill	$16.84M		$16.84M
YoY Change	0.0%		-8.95%
Intangibles			$0.00
YoY Change			-100.0%
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$33.78M	$33.78M	$24.94M
YoY Change	35.44%	35.65%	-36.5%
Total Long-Term Assets	$54.78M	$54.78M	$48.18M
YoY Change	13.68%	13.88%	-30.23%
TOTAL ASSETS
Total Short-Term Assets	$192.5M	$192.5M	$263.5M
Total Long-Term Assets	$54.78M	$54.78M	$48.18M
Total Assets	$247.3M	$247.3M	$311.6M
YoY Change	-20.66%	-20.65%	105.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.679M	$7.679M	$2.934M
YoY Change	161.72%	164.79%	-51.9%
Accrued Expenses	$7.151M	$12.75M	$6.501M
YoY Change	10.0%	116.17%	-67.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$0.00
YoY Change
Total Short-Term Liabilities	$21.00M	$21.00M	$15.11M
YoY Change	38.99%	39.07%	-58.01%
LONG-TERM LIABILITIES
Long-Term Debt	$142.4M	$142.4M	$128.2M
YoY Change	11.07%	11.07%	5.36%
Other Long-Term Liabilities	$3.917M	$5.624M	$4.212M
YoY Change	-7.0%	-7.8%	-52.53%
Total Long-Term Liabilities	$146.3M	$148.0M	$132.4M
YoY Change	10.49%	10.22%	1.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.00M	$21.00M	$15.11M
Total Long-Term Liabilities	$146.3M	$148.0M	$132.4M
Total Liabilities	$169.0M	$169.0M	$149.4M
YoY Change	13.16%	13.13%	-17.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$447.8M		-$384.2M
YoY Change	16.55%		-1.8%
Common Stock	$549.9M		$567.5M
YoY Change	-3.09%		30.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$0.00
YoY Change			-100.0%
Treasury Stock Shares			0.000 shares
Shareholders Equity	$78.24M	$78.24M	$162.3M
YoY Change
Total Liabilities & Shareholders Equity	$247.3M	$247.3M	$311.6M
YoY Change	-20.66%	-20.65%	105.79%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$22.30M	-$77.33M	-$11.28M
YoY Change	97.7%	-1200.3%	311.68%
Depreciation, Depletion And Amortization	$201.0K	$97.00K	$390.0K
YoY Change	-48.46%	-66.2%	-51.25%
Cash From Operating Activities	-$22.51M	-$77.31M	-$19.12M
YoY Change	17.71%	58.64%	131.48%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$26.00K	-$70.00K
YoY Change	-100.0%	-73.47%
Acquisitions
YoY Change
Other Investing Activities	$15.32M	$56.96M	$7.310M
YoY Change	109.58%	-181.81%	41.39%
Cash From Investing Activities	$15.32M	$56.93M	$7.240M
YoY Change	111.6%	-181.65%	40.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$263.0K	180.0K
YoY Change	-100.0%	-99.85%	-550.0%
NET CHANGE
Cash From Operating Activities	-22.51M	-$77.31M	-19.12M
Cash From Investing Activities	15.32M	$56.93M	7.240M
Cash From Financing Activities	0.000	$263.0K	180.0K
Net Change In Cash	-7.186M	-$21.01M	-11.70M
YoY Change	-38.58%	-133.92%	273.8%
FREE CASH FLOW
Cash From Operating Activities	-$22.51M	-$77.31M	-$19.12M
Capital Expenditures	$0.00	$26.00K	-$70.00K
Free Cash Flow	-$22.51M	-$77.34M	-$19.05M
YoY Change	18.14%	58.37%	130.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001012477
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-37977
CY2021	dei	Entity Registrant Name EntityRegistrantName	AVADEL PHARMACEUTICALS PLC
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1341933
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	10 Earlsfort Terrace
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2
CY2021	dei	Entity Address Country EntityAddressCountry	IE
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 T380
CY2021	dei	City Area Code CityAreaCode	1
CY2021	dei	Local Phone Number LocalPhoneNumber	901-5201
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	390167685	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59032237	shares
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22334000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59215000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5742000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12125000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17104000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20442000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32917000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68495000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32405000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30183000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	406000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	816000	USD
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	USD
CY2020	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	3327000	USD
CY2019	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	845000	USD
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	45760000	USD
CY2019	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2021	avdl	Restructuring Costs Net RestructuringCostsNet	-53000	USD
CY2020	avdl	Restructuring Costs Net RestructuringCostsNet	-43000	USD
CY2019	avdl	Restructuring Costs Net RestructuringCostsNet	6441000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	85546000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	16519000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	83327000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-85546000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	5815000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-24112000	USD
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	2126000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	-832000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	1069000	USD
CY2021	us-gaap	Interest Expense InterestExpense	9942000	USD
CY2020	us-gaap	Interest Expense InterestExpense	12994000	USD
CY2019	us-gaap	Interest Expense InterestExpense	12483000	USD
CY2021	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	217000	USD
CY2020	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	3364000	USD
CY2019	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	0	USD
CY2021	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2019	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-2678000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-435000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-378000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-93145000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5082000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38582000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15816000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12110000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5356000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-77329000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1228000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58535000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52996000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37403000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58535000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54941000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37403000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-77329000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1111000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-117000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	214000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-202000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-43000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1661000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	644000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	727000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2889000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1755000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	610000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-80218000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8783000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32616000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50708000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71722000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	106513000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	149680000	USD
CY2021Q4	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	2443000	USD
CY2020Q4	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	3326000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32826000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38726000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	192490000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	263454000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	285000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	359000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2652000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2604000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	16836000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	16836000	USD
CY2021Q4	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	1225000	USD
CY2020Q4	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	3445000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33777000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24939000	USD
CY2021Q4	us-gaap	Assets Assets	247265000	USD
CY2020Q4	us-gaap	Assets Assets	311637000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	900000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	474000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7679000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2934000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7151000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6501000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5270000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5200000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15109000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	142397000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	128210000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4212000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	169021000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1707000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1840000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3917000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	149371000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	488000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	488000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	488000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	488000	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	5000	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	5000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58620000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58620000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58396000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58396000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	586000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	583000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	549349000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	566916000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-447756000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384187000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23940000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21051000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	78244000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	162266000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	247265000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	311637000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2780000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	610000	USD
CY2019	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	118000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	519000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-29199000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1755000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2045000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60570000	USD
CY2020	avdl	Stock Issued During Period Value Public Offering StockIssuedDuringPeriodValuePublicOffering	116924000	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	144000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2999000	USD
CY2020	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	162266000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-77329000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2889000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	169000	USD
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	94000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8872000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	78244000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-77329000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	815000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1690000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2486000	USD
CY2021	avdl	Acquisition Related Contingent Consideration Remeasurement AcquisitionRelatedContingentConsiderationRemeasurement	0	USD
CY2020	avdl	Acquisition Related Contingent Consideration Remeasurement AcquisitionRelatedContingentConsiderationRemeasurement	3327000	USD
CY2019	avdl	Acquisition Related Contingent Consideration Remeasurement AcquisitionRelatedContingentConsiderationRemeasurement	845000	USD
CY2021	avdl	Financing Related Contingent Consideration Remeasurement FinancingRelatedContingentConsiderationRemeasurement	0	USD
CY2020	avdl	Financing Related Contingent Consideration Remeasurement FinancingRelatedContingentConsiderationRemeasurement	435000	USD
CY2019	avdl	Financing Related Contingent Consideration Remeasurement FinancingRelatedContingentConsiderationRemeasurement	378000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1248000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6524000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5995000	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	15666000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	7431000	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	6334000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8872000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2999000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	519000	USD
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	45760000	USD
CY2019	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2021	avdl	Noncash Gain Loss Deconsolidation Of Subsidiary NoncashGainLossDeconsolidationOfSubsidiary	0	USD
CY2020	avdl	Noncash Gain Loss Deconsolidation Of Subsidiary NoncashGainLossDeconsolidationOfSubsidiary	0	USD
CY2019	avdl	Noncash Gain Loss Deconsolidation Of Subsidiary NoncashGainLossDeconsolidationOfSubsidiary	-1750000	USD
CY2021	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	217000	USD
CY2020	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	3364000	USD
CY2019	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	0	USD
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1272000	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	142000	USD
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-254000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8281000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2471000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1352000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1155000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	439000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1863000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1187000	USD
CY2021	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-2796000	USD
CY2020	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-2213000	USD
CY2019	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	1014000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4232000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2788000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4641000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-114000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	895000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-13226000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	357000	USD
CY2021	avdl	Earn Out Payment In Excess Of Acquisition Date Fair Value EarnOutPaymentInExcessOfAcquisitionDateFairValue	0	USD
CY2020	avdl	Earn Out Payment In Excess Of Acquisition Date Fair Value EarnOutPaymentInExcessOfAcquisitionDateFairValue	5323000	USD
CY2019	avdl	Earn Out Payment In Excess Of Acquisition Date Fair Value EarnOutPaymentInExcessOfAcquisitionDateFairValue	10988000	USD
CY2021	us-gaap	Payments For Royalties PaymentsForRoyalties	0	USD
CY2020	us-gaap	Payments For Royalties PaymentsForRoyalties	866000	USD
CY2019	us-gaap	Payments For Royalties PaymentsForRoyalties	1748000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	3789000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	3126000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	4057000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77310000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48734000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38325000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	98000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	154000	USD
CY2021	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	16500000	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	25500000	USD
CY2019	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	102224000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	36284000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	63246000	USD
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	61769000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	131407000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	24648000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	56929000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-69721000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38723000	USD
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	60570000	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	116924000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	263000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2189000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	118000	USD
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-145000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	263000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	179683000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-27000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-896000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	720000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21014000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	61948000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	449000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71722000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9774000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9325000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50708000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71722000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9774000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	76000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1701000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	140000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	6469000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	6469000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	6469000	USD
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Reclassifications<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications are made to prior year amounts whenever necessary to conform with the current year presentation. Certain reclassifications have been made to the Consolidated Statements of Cash Flows for the fiscal year ended December 31, 2019 and balances within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14: Other Assets and Liabilities </span>for the year ended December 31, 2020 to condense line items of the same nature into a single line. This change does not affect previously reported net cash flows used in operating activities in the Consolidated Statements of Cash Flows.
CY2021	us-gaap	Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts	Allowance for Credit Losses. Amounts owed to the Company are presented net of an allowance that includes as assessment of expected credit losses. An allowance for credit losses is established based on expected losses. Expected losses are estimated by reviewing individual accounts, considering aging, financial condition of the debtor, payment history, current and forecast economic conditions and other relevant factors. To the extent that the Company identifies that any individual customer's credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of that customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, amounts are written off against the allowance when the related balances are no longer deemed collectible
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including marketable securities and contingent liabilities at the date of the consolidated financial statements and the reported amounts of sales and expenses during the periods presented. These estimates and assumptions are based on the best information available to management at the balance sheet dates and depending on the nature of the estimate can require significant judgments. Changes to these estimates and judgments can have and have had a material impact on the Company’s consolidated statements of (loss) income and balance sheets. Actual results could differ from those estimates under different assumptions or conditions.
CY2021	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	217000	USD
CY2020	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	3364000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	106812000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	948000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1247000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	106513000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	147903000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1815000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	38000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	149680000	USD
CY2021	avdl	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	174000	USD
CY2020	avdl	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	474000	USD
CY2019	avdl	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	483000	USD
CY2021	avdl	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	275000	USD
CY2020	avdl	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	912000	USD
CY2019	avdl	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	151000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	465000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1384000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	285000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	359000	USD
CY2021	us-gaap	Depreciation Depreciation	97000	USD
CY2020	us-gaap	Depreciation Depreciation	287000	USD
CY2019	us-gaap	Depreciation Depreciation	459000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	16836000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	16836000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	406000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	816000	USD
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	821000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1133000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1515000	USD
CY2021	us-gaap	Sublease Income SubleaseIncome	110000	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	336000	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	276000	USD
CY2021	us-gaap	Lease Cost LeaseCost	711000	USD
CY2020	us-gaap	Lease Cost LeaseCost	797000	USD
CY2019	us-gaap	Lease Cost LeaseCost	1239000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	578000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	769000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.049
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	974000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1013000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	614000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	206000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2807000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	200000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2607000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	142397000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	128210000	USD
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	9942000	USD
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	12994000	USD
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	12464000	USD
CY2020	avdl	Coupon Interest Expense CouponInterestExpense	6469000	USD
CY2021	avdl	Coupon Interest Expense CouponInterestExpense	6469000	USD
CY2019	avdl	Coupon Interest Expense CouponInterestExpense	6469000	USD
CY2018Q1	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	92.6956	Rate
CY2021Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	0	USD
CY2020Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	0	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5082000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38582000	USD
CY2020	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	14900000	USD
CY2020Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	0	USD
CY2018Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	28840000	USD
CY2019	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	12736000	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1223000	USD
CY2019Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	17327000	USD
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	6189000	USD
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	3762000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-93145000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-12810000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	60000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	20000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	97000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	60000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12790000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	97000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1256000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-15876000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	680000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4093000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-104000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15876000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	680000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5453000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15816000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12110000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5356000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11642000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-636000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4823000	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-8950000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1755000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1218000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	0	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	988000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	121000	USD
CY2021	avdl	Effective Income Tax Rate Reconciliation Intercompany Asset Transfer Amount EffectiveIncomeTaxRateReconciliationIntercompanyAssetTransferAmount	0	USD
CY2020	avdl	Effective Income Tax Rate Reconciliation Intercompany Asset Transfer Amount EffectiveIncomeTaxRateReconciliationIntercompanyAssetTransferAmount	0	USD
CY2019	avdl	Effective Income Tax Rate Reconciliation Intercompany Asset Transfer Amount EffectiveIncomeTaxRateReconciliationIntercompanyAssetTransferAmount	-8190000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4296000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4231000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7379000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	645000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1060000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1039000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-9328000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	239000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-274000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-261000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	60000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	20000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	-9124000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	0	USD
CY2021	avdl	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount	2173000	USD
CY2020	avdl	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount	1728000	USD
CY2019	avdl	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount	982000	USD
CY2021	avdl	Effective Income Tax Rate Reconciliation Amount Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit	1524000	USD
CY2020	avdl	Effective Income Tax Rate Reconciliation Amount Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit	2793000	USD
CY2019	avdl	Effective Income Tax Rate Reconciliation Amount Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit	0	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-1113000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	263000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-378000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15816000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12110000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5356000	USD
CY2021	avdl	Increase Decrease In Income Tax Benefit IncreaseDecreaseInIncomeTaxBenefit	3706000	USD
CY2020	avdl	Increase Decrease In Income Tax Benefit IncreaseDecreaseInIncomeTaxBenefit	6754000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3143000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6465000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5315000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	2416000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1266000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	3322000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3143000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3143000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6465000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2483000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2483000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3806000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	239000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	203000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	555000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1777000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1475000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35990000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31302000	USD
CY2021Q4	avdl	Deferred Tax Assets Tax Credit Carryforwards Orphan Drug And Research DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch	4964000	USD
CY2020Q4	avdl	Deferred Tax Assets Tax Credit Carryforwards Orphan Drug And Research DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch	2793000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4108000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2626000	USD
CY2021Q4	avdl	Deferred Tax Assets Amortizationof Intangible Assets DeferredTaxAssetsAmortizationofIntangibleAssets	3429000	USD
CY2020Q4	avdl	Deferred Tax Assets Amortizationof Intangible Assets DeferredTaxAssetsAmortizationofIntangibleAssets	3701000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	662000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	423000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	49153000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40845000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	925000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	890000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	75000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	75000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1000000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	965000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24025000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21624000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	24128000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	18256000	USD
CY2021	us-gaap	Undistributed Earnings UndistributedEarnings	3916000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3668000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6771000	USD
CY2020	avdl	Coronavirus Aid Relief And Economic Security Act Cares Act Changein Tax Rate Deferred Tax Liability Income Tax Benefit CoronavirusAidReliefAndEconomicSecurityActCARESActChangeinTaxRateDeferredTaxLiabilityIncomeTaxBenefit	9124000	USD
CY2020	avdl	Cares Act Proceeds From Income Tax Refunds CARESActProceedsFromIncomeTaxRefunds	3351000	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	29097000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	18615000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3179000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1018000	USD
CY2021Q4	avdl	Guarantee Current GuaranteeCurrent	279000	USD
CY2020Q4	avdl	Guarantee Current GuaranteeCurrent	318000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	271000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	798000	USD
CY2021Q4	avdl	Short Term Note Receivable ShortTermNoteReceivable	0	USD
CY2020Q4	avdl	Short Term Note Receivable ShortTermNoteReceivable	16500000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	1477000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32826000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38726000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	24128000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	18256000	USD
CY2021Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	8549000	USD
CY2020Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	5201000	USD
CY2021Q4	avdl	Guarantee Noncurrent GuaranteeNoncurrent	771000	USD
CY2020Q4	avdl	Guarantee Noncurrent GuaranteeNoncurrent	1050000	USD
CY2021Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	329000	USD
CY2020Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	432000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33777000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24939000	USD
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3167000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1697000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2678000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2781000	USD
CY2021Q4	avdl	Accrued Outsource Contract Costs AccruedOutsourceContractCosts	1048000	USD
CY2020Q4	avdl	Accrued Outsource Contract Costs AccruedOutsourceContractCosts	473000	USD
CY2021Q4	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	217000	USD
CY2020Q4	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	1030000	USD
CY2021Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	41000	USD
CY2020Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	520000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7151000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6501000	USD
CY2021Q4	avdl	Accrued Interest Current AccruedInterestCurrent	4920000	USD
CY2020Q4	avdl	Accrued Interest Current AccruedInterestCurrent	2695000	USD
CY2021Q4	avdl	Other Guarantor Obligations Current Carrying Value OtherGuarantorObligationsCurrentCarryingValue	280000	USD
CY2020Q4	avdl	Other Guarantor Obligations Current Carrying Value OtherGuarantorObligationsCurrentCarryingValue	319000	USD
CY2021Q4	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	70000	USD
CY2020Q4	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	160000	USD
CY2021Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	0	USD
CY2020Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	2026000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5270000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5200000	USD
CY2021Q4	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	3143000	USD
CY2020Q4	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	3159000	USD
CY2021Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	774000	USD
CY2020Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	1053000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3917000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4212000	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	5500000	USD
CY2021	avdl	Costs Incurred Purchase Obligation CostsIncurredPurchaseObligation	3348000	USD
CY2021Q4	avdl	Contractual Obligation Annual Amount ContractualObligationAnnualAmount	3000000	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58620000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58620000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	488000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	488000	shares
CY2020Q1	avdl	Maximum Aggregate Offering Priceof Securities Under Shelf Registration MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration	250000	USD
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	avdl	Maximum Aggregate Offering Priceof American Depositary Shares Under Shelf Registration MaximumAggregateOfferingPriceofAmericanDepositarySharesUnderShelfRegistration	50000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	428000	USD
CY2020Q1	avdl	Maximum Threshold Percentage For Trigger Of Convertible Preferred Stock MaximumThresholdPercentageForTriggerOfConvertiblePreferredStock	0.0999
CY2020Q3	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	5407000	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8872000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2999000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	519000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18429000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y2M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5898000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.02
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2857000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.20
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	48000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.54
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	234000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.13
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	70000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	12.62
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8403000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.39
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M29D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12204000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3256000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.88
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M17D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6291000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6291000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1841000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	572000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.36
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.63
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.24
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58535000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52996000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37403000	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1945000	shares
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58535000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54941000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37403000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15327000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14915000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16740000	shares
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	214000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-202000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-43000	USD
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22334000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59215000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22334000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59215000	USD
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	29422000	USD
CY2020Q4	us-gaap	Noncurrent Assets NoncurrentAssets	26482000	USD
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	29694000	USD
CY2021	dei	Auditor Name AuditorName	Deloitte and Touche LLP
CY2021	dei	Auditor Location AuditorLocation	St. Louis, Missouri
CY2021	dei	Auditor Firm AuditorFirmId	34

Files In Submission

Name	View Source	Status
0001012477-22-000004-index-headers.html	Edgar Link	pending
0001012477-22-000004-index.html	Edgar Link	pending
0001012477-22-000004.txt	Edgar Link	pending
0001012477-22-000004-xbrl.zip	Edgar Link	pending
a123121ex-1020.htm	Edgar Link	pending
a123121ex-1021.htm	Edgar Link	pending
a123121ex-1021001.jpg	Edgar Link	pending
a123121ex-1021002.jpg	Edgar Link	pending
a123121ex-1021003.jpg	Edgar Link	pending
a123121ex-1021004.jpg	Edgar Link	pending
a123121ex-1021005.jpg	Edgar Link	pending
a123121ex-1021006.jpg	Edgar Link	pending
a123121ex-1021007.jpg	Edgar Link	pending
a123121ex-1021008.jpg	Edgar Link	pending
a123121ex-1021009.jpg	Edgar Link	pending
a123121ex-1021010.jpg	Edgar Link	pending
a123121ex-1021011.jpg	Edgar Link	pending
a123121ex-1021012.jpg	Edgar Link	pending
a123121ex-1021013.jpg	Edgar Link	pending
a123121ex-1021014.jpg	Edgar Link	pending
a123121ex-1021015.jpg	Edgar Link	pending
a123121ex-1021016.jpg	Edgar Link	pending
a123121ex-1021017.jpg	Edgar Link	pending
a123121ex-1021018.jpg	Edgar Link	pending
a123121ex-1021019.jpg	Edgar Link	pending
a123121ex-211.htm	Edgar Link	pending
a123121ex-231.htm	Edgar Link	pending
a123121ex-311.htm	Edgar Link	pending
a123121ex-312.htm	Edgar Link	pending
a123121ex-321.htm	Edgar Link	pending
a123121ex-322.htm	Edgar Link	pending
avdl-20211231.htm	Edgar Link	pending
avdl-20211231.xsd	Edgar Link	pending
avdl-20211231_cal.xml	Edgar Link	unprocessable
avdl-20211231_def.xml	Edgar Link	unprocessable
avdl-20211231_g1.jpg	Edgar Link	pending
avdl-20211231_htm.xml	Edgar Link	completed
avdl-20211231_lab.xml	Edgar Link	unprocessable
avdl-20211231_pre.xml	Edgar Link	unprocessable
ex1022avadel-formofexchang.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

2021 Q4 Form 10-K Financial Statement

#000101247722000004 Filed on March 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL AVADEL PHARMACEUTICALS PLC Stock $avdl

2021 Q4 Form 10-K Financial Statement

#000101247722000004 Filed on March 16, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl